40kD pegylated interferon alpha 2a plus ribavirin compared to 40 kD pegylated interferon alpha 2a plus ribavirin and mycophenolate in the management of patients with refractory chronic HCV infection

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN52566041

Enrollment

Registered

2004-09-30

Start date

2002-04-01

Completion date

Unknown

Last updated

2018-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C Infections and Infestations Chronic viral hepatitis

Interventions

Randomised, prospective trial.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 60 patients in each arm - 15-25 from Chelsea and Westminster NHS Trust

Exclusion criteria

Exclusion criteria: Does not meet inclusion criteria

Design outcomes

Primary

Measure	Time frame
Sustained response 24-28 weeks post completion of therapy	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026